Volume 5, Number 6—December 1999
Synopsis
Antimicrobial Resistance with Streptococcus pneumoniae in the United States, 1997–98
Gary V. Doern
, Angela B. Brueggemann, Holly Huynh, Elizabeth Wingert, and Paul Rhomberg
, Angela B. Brueggemann, Holly Huynh, Elizabeth Wingert, and Paul Rhomberg
Table 3
Recovery of Streptococcus pneumoniae strains with intermediate and high levels of resistance, by specimen source and patient characteristics
| Characteristic | Total no. of isolates | No. (%) of resistant isolates for the following antimicrobial drugs |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Penicillin |
Ceftriaxone |
Erythromycin |
Tetracycline |
TMP/SMX Chloramphenicol |
|||||||||
| I | R | I | R | I | R | I | R | I | R | I | R | ||
| Specimen sourcea | |||||||||||||
| LRT | 773 | 144 | 103 | 91 | 36 | 5 | 152 | 1 | 116 | 89 | 149 | -- | 67 |
| (18.6) | (13.3) | (11.8) | (4.7) | (0.6) | (20.9) | (0.1) | (15.0) | (11.5) | (19.3) | (8.7) | |||
| Blood | 509 | 68 | 41 | 35 | 16 | 1 | 59 | 2 | 33 | 40 | 87 | -- | 17 |
| (13.4) | (8.1) | (6.9) | (3.1) | (0.2) | (11.6) | (0.4) | (6.5) | (7.9) | (17.1) | (3.3) | |||
| URT | 238 | 50 | 48 | 44 | 11 | 0 | 77 | 2 | 53 | 28 | 74 | -- | 28 |
| (21.0) | (20.2) | (18.5) | (4.6) | (0.0) | (32.4) | (0.8) | (22.3) | (11.8) | (31.1) | (11.8) | |||
| BF/CSF | 60 | 12 | 3 | 4 | 1 | 0 | 9 | 0 | 3 | 1 | 13 | -- | 2 |
| (20.0) | (5.0) | (6.7) | (1.7) | (0.0) | (15.0) | (0.0) | (5.0) | (1.7) | (21.7) | (3.3) | |||
| Other | 21 | 4 | 1 | 1 | 0 | 0 | 5 | 0 | 1 | 2 | 3) | -- | 1 |
| (19.0) | (4.8) | (4.8) | (0.0) | (0.0) | (23.8) | (0.0) | (4.8) | (9.5) | (14.3) | (4.8) | |||
| Age group (years) | |||||||||||||
| <5 | 432 | 88 | 79 | 72 | 23 | 1 | 115 | 3 | 71 | 62 | 128 | -- | 42 |
| (20.4) | (18.3) | (16.7) | (5.3) | (0.2) | (26.6) | (0.7) | (16.4) | (14.4) | (29.6) | (9.7) | |||
| 6-20 | 97 | 14 | 6 | 6 | 1 | 0 | 12 | 0 | 11 | 11 | 14 | -- | 4 |
| (14.4) | (6.2) | (6.2) | (1.0) | (0.0) | (12.4) | (0.0) | (11.3) | (11.3) | (14.4) | (4.1) | |||
| 21-50 | 407 | 76 | 42 | 39 | 18 | 2 | 71 | 0 | 56 | 32 | 80 | -- | 22 |
| (18.7) | (10.6) | (9.6) | (4.4) | (0.5) | (17.4) | (0.0) | (13.8) | (7.9) | (19.7) | (5.4) | |||
| >50 | 652 | 96 | 68 | 57 | 22 | 3 | 102 | 2 | 66 | 65 | 102 | -- | 46 |
| (14.7) | (10.4) | (8.7) | (3.4) | (0.5) | (15.6) | (0.3) | (10.1) | (10.0) | (15.6) | (7.1) | |||
| Service | |||||||||||||
| Inpatient | 969 | 172 | 111 | 104 | 37 | 3 | 171 | 3 | 107 | 85 | 192 | -- | 61 |
| (17.8) | (11.5) | (10.7) | (3.8) | (0.3) | (17.6) | (0.3) | (11.0) | (8.8) | (19.8) | (6.3) | |||
| Outpatient | 628 | 106 | 85 | 71 | 27 | 3 | 131 | 2 | 99 | 86 | 134 | -- | 54 |
| (16.9) | (13.5) | (11.3) | (4.3) | (0.3) | (20.9) | (0.3) | (15.8) | (13.7) | (21.3) | (8.6) | |||
aBF/CSF, body fluids/cerebrospinal fluid; LRT, lower respiratory tract; URT = upper respiratory tract.
TMP/SMX, trimethoprim/sulfamethoxazole.
Page created: December 15, 2010
Page updated: December 15, 2010
Page reviewed: December 15, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.